Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 7,741 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Daniel Janney sold 7,741 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $275.63, for a total value of $2,133,651.83. Following the completion of the sale, the director directly owned 85,096 shares of the company’s stock, valued at approximately $23,455,010.48. This trade represents a 8.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Daniel Janney also recently made the following trade(s):

• On Wednesday, February 25th, Daniel Janney sold 700 shares of Krystal Biotech stock. The stock was sold at an average price of $275.00, for a total transaction of $192,500.00.
• On Tuesday, February 24th, Daniel Janney sold 13,825 shares of Krystal Biotech stock. The stock was sold at an average price of $268.34, for a total value of $3,709,800.50.
• On Tuesday, February 24th, Daniel Janney sold 37,895 shares of Krystal Biotech stock. The shares were sold at an average price of $266.88, for a total value of $10,113,417.60.

Krystal Biotech Stock Performance

Shares of KRYS opened at $276.36 on Friday. The firm has a market cap of $8.08 billion, a PE ratio of 40.34 and a beta of 0.49. The firm’s 50 day moving average price is $268.29 and its 200 day moving average price is $213.42. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The company had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in KRYS. Royal Bank of Canada grew its holdings in shares of Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC lifted its position in Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after buying an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new stake in Krystal Biotech during the first quarter worth $218,000. Finally, CWM LLC increased its holdings in Krystal Biotech by 7.2% in the 2nd quarter. CWM LLC now owns 1,583 shares of the company’s stock valued at $218,000 after buying an additional 107 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on KRYS shares. Bank of America lifted their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Guggenheim boosted their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Citigroup boosted their price objective on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Moderate Buy” and a consensus target price of $326.25.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.